Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene

Cell

Volumn 129, Issue 6, 2007, Pages 1065-1079

  Boehm, Jesse S ^a,c   Zhao, Jean J ^a,b   Yao, Jun ^a   Kim, So Young ^a,b,c   Firestein, Ron ^a,b,c   Dunn, Ian F ^a,b,c   Sjostrom, Sarah K ^a,c   Garraway, Levi A ^a,b,c   Weremowicz, Stanislawa ^b   Richardson, Andrea L ^b   Greulich, Heidi ^a,b,c   Stewart, Carly J ^a,c   Mulvey, Laura A ^a   Shen, Rhine R ^a,c   Ambrogio, Lauren ^a,c   Hirozane Kishikawa, Tomoko ^a   Hill, David E ^a   Vidal, Marc ^a   Meyerson, Matthew ^a,b,c   Grenier, Jennifer K ^c   Hinkle, Greg ^a,c   Root, David E ^c   Roberts, Thomas M ^a   Lander, Eric S ^c   Polyak, Kornelia ^a,b   Hahn, William C ^a,b,c   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ALLELE; ANIMAL CELL; ARTICLE; BREAST CARCINOGENESIS; CANCER CELL CULTURE; CELL DEATH; CELL TRANSFORMATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ANALYSIS; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REPRESSION; GENE STRUCTURE; GENETIC COMPLEMENTATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NONHUMAN; ONCOGENE; OPEN READING FRAME; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 34249993765     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2007.03.052     Document Type: Article

References (55)

1. Adli M., and Baldwin A.S. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J. Biol. Chem. 281 (2006) 26976-26984
2. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., Flanagan A., Teague J., Futreal P.A., Stratton M.R., et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91 (2004) 355-358
3. Bartkova J., Lukas J., Muller H., Lutzhoft D., Strauss M., and Bartek J. Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57 (1994) 353-361
4. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 (2004) 431-437
5. Biswas D.K., Shi Q., Baily S., Strickland I., Ghosh S., Pardee A.B., and Iglehart J.D. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. USA 101 (2004) 10137-10142
6. Boehm J.S., Hession M.T., Bulmer S.E., and Hahn W.C. Transformation of human and murine fibroblasts without viral oncoproteins. Mol. Cell. Biol. 25 (2005) 6464-6474
7. Brown K., Gerstberger S., Carlson L., Franzoso G., and Siebenlist U. Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267 (1995) 1485-1488
8. Brunet A., Pages G., and Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 9 (1994) 3379-3387
9. Chien Y., Kim S., Bumeister R., Loo Y.M., Kwon S.W., Johnson C.L., Balakireva M.G., Romeo Y., Kopelovich L., Gale Jr. M., et al. RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127 (2006) 157-170
10. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., Hollstein P.E., MacCollin M., and Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10 (2006) 459-472
11. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
12. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3 (2003) 11-22
13. Dupuy A.J., Jenkins N.A., and Copeland N.G. Sleeping beauty: a novel cancer gene discovery tool. Hum. Mol. Genet. 15 Spec No 1 (2006) R75-R79
14. Eddy S.F., Guo S., Demicco E.G., Romieu-Mourez R., Landesman-Bollag E., Seldin D.C., and Sonenshein G.E. Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res. 65 (2005) 11375-11383
15. Elenbaas B., Spirio L., Koerner F., Fleming M.D., Zimonjic D.B., Donaher J.L., Popescu N.C., Hahn W.C., and Weinberg R.A. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15 (2001) 50-65
16. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., Coyle A.J., Liao S.M., and Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4 (2003) 491-496
17. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., Beroukhim R., Milner D.A., Granter S.R., Du J., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
18. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468
19. Hamad N.M., Elconin J.H., Karnoub A.E., Bai W., Rich J.N., Abraham R.T., Der C.J., and Counter C.M. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16 (2002) 2045-2057
20. Harris J., Oliere S., Sharma S., Sun Q., Lin R., Hiscott J., and Grandvaux N. Nuclear accumulation of cRel following C-terminal phosphorylation by TBK1/IKK{epsilon}. J. Immunol. 177 (2006) 2527-2535
21. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2 (2002) 301-310
22. Kim M., Gans J.D., Nogueira C., Wang A., Paik J.H., Feng B., Brennan C., Hahn W.C., Cordon-Cardo C., Wagner S.N., et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125 (2006) 1269-1281
23. Klippel A., Reinhard C., Kavanaugh W.M., Apell G., Escobedo M.A., and Williams L.T. Membrane localization of phosphatidylinositol 3-kinase is sufficient to activate multiple signal-transducing kinase pathways. Mol. Cell. Biol. 16 (1996) 4117-4127
24. Kohn A.D., Takeuchi F., and Roth R.A. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J. Biol. Chem. 271 (1996) 21920-21926
25. Kolfschoten I.G., van Leeuwen B., Berns K., Mullenders J., Beijersbergen R.L., Bernards R., Voorhoeve P.M., and Agami R. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121 (2005) 849-858
26. Kuranaga E., Kanuka H., Tonoki A., Takemoto K., Tomioka T., Kobayashi M., Hayashi S., and Miura M. Drosophila IKK-related kinase regulates nonapoptotic function of caspases via degradation of IAPs. Cell 126 (2006) 583-596
27. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
28. MacKeigan J.P., Murphy L.O., and Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Biol. 7 (2005) 591-600
29. Moffat J., Grueneberg D.A., Yang X., Kim S.Y., Kloepfer A.M., Hinkle G., Piqani B., Eisenhaure T.M., Luo B., Grenier J.K., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124 (2006) 1283-1298
30. Morgenstern J.P., and Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18 (1990) 3587-3596
31. Morrison C., Radmacher M., Mohammed N., Suster D., Auer H., Jones S., Riggenbach J., Kelbick N., Bos G., and Mayerson J. MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. J. Clin. Oncol. 23 (2005) 9369-9376
32. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441 (2006) 106-110
33. Oshima K., Takeda M., Kuranaga E., Ueda R., Aigaki T., Miura M., and Hayashi S. IKKvarepsilon regulates F actin assembly and interacts with Drosophila IAP1 in cellular morphogenesis. Curr. Biol. 16 (2006) 1531-1537
34. Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., and Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401 (1999) 82-85
35. Paddison P.J., Silva J.M., Conklin D.S., Schlabach M., Li M., Aruleba S., Balija V., O'Shaughnessy A., Gnoj L., Scobie K., et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 428 (2004) 427-431
36. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
37. Peeper D.S., Shvarts A., Brummelkamp T., Douma S., Koh E.Y., Daley G.Q., and Bernards R. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat. Cell Biol. 4 (2002) 148-153
38. Peters R.T., Liao S.M., and Maniatis T. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol. Cell 5 (2000) 513-522
39. Rangarajan A., Hong S.J., Gifford A., and Weinberg R.A. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 6 (2004) 171-183
40. Rennstam K., Ahlstedt-Soini M., Baldetorp B., Bendahl P.O., Borg A., Karhu R., Tanner M., Tirkkonen M., and Isola J. Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res. 63 (2003) 8861-8868
41. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
42. Rowland B.D., Bernards R., and Peeper D.S. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat. Cell Biol. 7 (2005) 1074-1082
43. Rual J.F., Hirozane-Kishikawa T., Hao T., Bertin N., Li S., Dricot A., Li N., Rosenberg J., Lamesch P., Vidalain P.O., et al. Human ORFeome version 1.1: a platform for reverse proteomics. Genome Res. 14 (2004) 2128-2135
44. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
45. Shapiro R.S., and Anderson K.V. Drosophila Ik2, a member of the I kappa B kinase family, is required for mRNA localization during oogenesis. Development 133 (2006) 1467-1475
46. Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R., and Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 300 (2003) 1148-1151
47. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., and Sonenshein G.E. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 100 (1997) 2952-2960
48. Stanton Jr. V.P., Nichols D.W., Laudano A.P., and Cooper G.M. Definition of the human raf amino-terminal regulatory region by deletion mutagenesis. Mol. Cell. Biol. 9 (1989) 639-647
49. Tenoever B.R., Ng S.L., Chua M.A., McWhirter S.M., Garcia-Sastre A., and Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 315 (2007) 1274-1278
50. Weinstein I.B., and Joe A.K. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3 (2006) 448-457
51. Westbrook T.F., Martin E.S., Schlabach M.R., Leng Y., Liang A.C., Feng B., Zhao J.J., Roberts T.M., Mandel G., Hannon G.J., et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 121 (2005) 837-848
52. Yao J., Weremowicz S., Feng B., Gentleman R.C., Marks J.R., Gelman R., Brennan C., and Polyak K. Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression. Cancer Res. 66 (2006) 4065-4078
53. Zender L., Spector M.S., Xue W., Flemming P., Cordon-Cardo C., Silke J., Fan S.T., Luk J.M., Wigler M., Hannon G.J., et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (2006) 1253-1267
54. Zhao J.J., Roberts T.M., and Hahn W.C. Functional genetics and experimental models of human cancer. Trends Mol. Med. 10 (2004) 344-350
55. Zhao X., Weir B.A., LaFramboise T., Lin M., Beroukhim R., Garraway L., Beheshti J., Lee J.C., Naoki K., Richards W.G., et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65 (2005) 5561-5570